Larvol Delta - Asher-Bio-to-Present-Preclinical-ProofofConcept-Data-for-AB248-a-Highly-Selective-CD8targeted-IL2-Therapy-at-SITC-2021

AB248 - Asher Biotherap

https://www.businesswire.com/news/home/20211001005077/en/Asher-Bio-to-Present-Preclinical-Proof-of-Concept-Data-for-AB248-a-Highly-Selective-CD8-targeted-IL-2-Therapy-at-SITC-2021

Oct 1, 2021

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next